Akebia Therapeutics to Participate in Virtual Kidney Health Forum

WALTHAM, Mass., Oct. 07, 2026 /CourierPR/ -- Akebia Therapeutics, a biopharmaceutical company dedicated to improving the lives of those affected by kidney disease, is set to participate in one-on-one meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026. The company, founded in 2007 and headquartered in Waltham, Massachusetts, will be represented by its Chief Executive Officer, John P. Butler; Chief R&D and Medical Officer, Dr. Steven Burke; and Chief Financial and Chief Business Officer, Erik Ostrowski.

During these meetings, the management team will discuss the company's commercial products and its clinical pipeline, which includes differentiated assets for rare kidney diseases. Akebia Therapeutics aims to leverage these discussions to further advance its research and development efforts, potentially opening new avenues for treatment and care in the kidney disease community.

Founded in 2007, Akebia Therapeutics has been at the forefront of developing innovative therapies for rare kidney diseases. The company's commitment to addressing unmet medical needs in this field is reflected in its diverse portfolio of products and ongoing clinical trials. By participating in the Virtual U.S. Bancorp I BTIG Kidney Health Forum, Akebia Therapeutics seeks to engage with key stakeholders and share insights on its progress and future plans.

The forum, which is designed to bring together industry leaders, researchers, and healthcare professionals, provides a platform for Akebia Therapeutics to showcase its advancements and collaborate with other experts in the field. This engagement is crucial for the company as it continues to navigate the complex landscape of kidney disease treatment and seeks to bring new therapies to market.

Akebia Therapeutics' participation in the forum underscores its ongoing dedication to advancing the field of kidney disease research and treatment. Through these meetings, the company hopes to foster partnerships and collaborations that will drive innovation and improve patient outcomes.